Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

Mykor's £4m grows panels from mushrooms

3 min read
16:30UTC

Bristol's Mykor raised £4m on 27 May to grow building panels from mycelium, with £337m in orders signed before the first panel ships. Demand proven ahead of production, the opposite of most cleantech risk.

TechnologyDeveloping
Key takeaway

Mykor booked £337m in orders before shipping a single panel, inverting the usual cleantech risk.

Mykor, a Bristol company, raised £4m on Wednesday 27 May, led by the Clean Growth Fund with co-investors The FSE Group and Green Angel Ventures plus an Innovate UK grant, taking total funding to £7.5m⁠1. Mykor grows structural insulated panels from engineered mycelium, the root structure of fungi, and agricultural waste. The panels, branded MykoSIP, carry 60% less embodied carbon than conventional insulation and a Euroclass B fire rating, the European standard for limited combustibility. Co-founders Olivia Page and Valentina Dipietro are Forbes 30 Under 30 honourees, and the company employs 22 staff.

The number that separates Mykor from most cleantech is the order book: £337m in pre-production commercial agreements signed with UK and European contractors⁠2. That figure matters because it is signed before the first panel ships, which inverts the usual cleantech risk. Most materials startups burn capital proving a market exists; Mykor has booked demand and now needs to build supply. The £4m funds production capacity against contracts already in hand, not a hope that buyers will appear.

A Bristol firm with 22 staff is a different animal from a London AI raise, and that is the point. The regional, non-Golden-Triangle deeptech tier is alive, echoing earlier rounds outside the south-east such as Rivan's £25m for a synthetic-gas plant in Wiltshire and the regional life-sciences manufacturing sites the Life Sciences Innovative Manufacturing Fund backed in April. These companies raise from cleantech specialists and grant bodies, not the funds chasing the next billion-dollar AI label, which is exactly why the aggregate capital figures pass them by while the work goes on.

Deep Analysis

In plain English

Most building insulation, the material packed into walls to keep heat in, comes from mineral wool (rock or glass fibres) or plastic foam. Both require energy-intensive industrial processes to make, which creates carbon emissions before the building even opens. This is called 'embodied carbon'. Mykor grows its panels from mycelium, the root-like network of a fungus, combined with agricultural waste like straw or husks. The mycelium binds the waste material together into a rigid panel. Growing the panels uses far less energy than manufacturing conventional insulation, so the embodied carbon is roughly 60% lower. The fire rating matters because buildings have to pass fire safety tests; Mykor's panels have achieved a Euroclass B rating, which means they meet the standard required for most commercial and residential construction. The £337m in pre-production agreements means large building contractors have already committed to buy these panels once production scales up, before the first production line reaches full volume.

Deep Analysis
Root Causes

UK construction's embodied-carbon problem persists for two reasons operating at different speeds. In the short term, procurement departments at large contractors price on upfront material cost rather than whole-life carbon cost, because planning and building regulations do not yet require embodied-carbon reporting.

Mykor's pre-production agreements are an early signal that the 2025 Future Homes Standard consultation, which proposed mandatory whole-life carbon assessments, is already shifting contractor behaviour ahead of legal requirement.

In the medium term, the clean-build materials market lacks a domestic institutional anchor comparable to Longwall for deeptech. The Clean Growth Fund, which led Mykor's round, is the primary UK-domiciled cleantech early-stage vehicle at this cheque size. Innovate UK grant co-funding supplements equity but does not replace it. The result is a concentration of supply: if Clean Growth Fund's follow-on appetite changes, Mykor's next round has limited alternative domestic leads.

What could happen next?
  • Opportunity

    The £337m pre-production pipeline, if it converts at standard construction industry lead times of 2-4 years, would take Mykor from a £7.5m funded startup to a company with material revenue comparable to its total funding raise, without requiring additional equity.

  • Risk

    Installer-skills gaps for biogenic panel systems could delay conversion of the pre-production pipeline; the Ecovative precedent shows 4-6 year lags between signing and volume delivery for novel materials.

First Reported In

Update #6 · Orbital's $50m has no UK lead

Tech Funding News· 29 May 2026
Read original →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.